By Matthew Bultman (June 21, 2018, 9:04 PM EDT) -- The Patent Trial and Appeal Board has not been the graveyard for drug patents that some might expect as it's been invalidating these patents at virtually the same rate as district courts, according to a new study that challenges some of the conventional wisdom about the PTAB.
The analysis, conducted by attorneys at Ropes & Gray LLP, looked at all America Invents Act reviews involving patents for approved drug products through May 1. It also considered district court decisions in lawsuits over generic drugs during roughly the same time.
Here are some of the big takeaways.
PTAB Impressions May Be Too...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!